Pharmaceutical Giant Eli Lilly Suspends 340B Drug Discounts Over Data Submission Dispute with Hospitals

A growing conflict between pharmaceutical company Eli Lilly and American hospitals intensified last week when Lilly moved to withhold critical drug discounts from participating healthcare providers.

The company has been pressing hospitals to submit detailed claims data demonstrating that discounted medications under the 340B Drug Pricing Program are actually reaching eligible low-income patients. Lilly announced this requirement in January and set a February 1 compliance deadline for approximately 1,000 hospitals, followed by months of additional correspondence before implementing the discount suspension.

The 340B program, established by Congress in 1992, enables qualified safety-net hospitals and clinics to purchase outpatient medications at significantly reduced prices, aiming to improve care access for vulnerable populations.

Lilly maintains that the program is being exploited by large health systems that collect discounts on drugs not delivered to qualifying patients. The company claims the data submission requirement is necessary to prevent this misuse and protect the program’s integrity.

Hospital associations strongly dispute Lilly’s approach, arguing the policy imposes unreasonable administrative burdens on already overextended providers. The American Hospital Association contends the manufacturer’s actions are legally questionable and urges federal oversight to prevent private companies from unilaterally altering 340B program requirements.

“Congress did not authorize drug companies to establish their own reporting standards and subsequently penalize hospitals for non-compliance,” stated Maureen Testoni, CEO of 340B Health, which represents participating providers. “This creates a concerning precedent that could deter other manufacturers from joining the program.”

Novo Nordisk implemented a comparable data requirement policy in April, suggesting a broader industry shift. Healthcare advocates warn that without federal intervention, additional pharmaceutical companies may adopt similar restrictions, potentially limiting medication access for low-income patients.

Federal agencies including HHS and HRSA have not yet publicly responded to the escalating situation, leaving hospital groups concerned about the lack of official guidance on the matter.

Source link